Natco Pharma Ltd. NSE: NATCOPHARM | BSE: 524816

Strong Performer, Under Radar

Download real time

858.80 6.65 (0.78%)

45.75% Fall from 52W High

131.3K

NSE+BSE Volume

NSE 17 Sep, 2025 11:26 AM (IST)

Natco Pharma Ltd. share price target

Natco Pharma Ltd. has an average share price target of 1297.50. The consensus estimate represents an upside of 51.08% from the last price of 858.80. View 5 reports from 4 analysts offering long-term price targets for Natco Pharma Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	17 Sep 2025	Natco Pharma	Consensus Share Price Target	858.80	982.64	-	14.42	hold	pdf Detailed Estimates
	09 Feb 2018	Natco Pharma	HDFC Securities	858.80		811.00 (5.89%)		Results Update	pdf post cache		Broker Report Natco Pharma Ltd Q3FY18 results comment HDFC Securities Natco Pharma Ltd Q3FY18 results comment Revenue grew by 31.76% to Rs. 562.2 Cr in Q3FY18 when compared to the previous quarter. On the other hand, it decreased by 16.08% when compared with Q3FY17. pdf Copy Link Share on Share on Share on Share on Alert
	11 Dec 2017	Natco Pharma	Karvy Target	858.80	1132.00	960.70 (-10.61%)		Buy	pdf post cache		Broker Report Natco Pharma Ltd: Limited Competition Specialty Generics in ... (Dec 11, 2017) Karvy gCopaxone and gTamiflu Provide Significant Opportunity: Natco's partner Mylan launched gCopaxone both 20mg and 40mg. All patents expired for 20mg but 40mg patent litigation is ongoing, thus 40mg is an at-risk launch. The 40mgversion is protected by 5 orange book patents, claims of 4 of these patents were held invalid by District Court and litigation of the fifth patent issued in Aug 2016 was dismissed with prejudice. pdf Copy Link Share on Share on Share on Share on Alert
	09 Nov 2017	Natco Pharma	Axis Direct Target	858.80	1150.00	911.85 (-5.82%)		Buy	pdf post cache		Broker Report Result Update:Natco Pharma Axis Direct Though Q2 revenue declined 9% YoY (on a high base), EBITDA and PAT grew 16% and 27% led by higher-margin limited-competition product gDoxil in US. We expect strong PAT growth of 113% in H2 driven by gCopaxone, gDoxil, gTamiflu OS. pdf Copy Link Share on Share on Share on Share on Alert
	06 Nov 2017	Natco Pharma	ICICI Securities Limited Reco Target	858.80	1190.00	961.45 (-10.68%)		Buy	pdf post cache		Broker Report Natco Pharma Limited ICICI Securities Limited ICICI Securities Ltd \| Retail Equity Research Revenues declined 7% YoY to \| 427 crore (I-direct estimate: \| 496 crore). The revenues were lower than I-direct estimates mainly due to increase in competition in Hep C sales EBITDA margins improved 580 bps YoY to 28.6% (I-direct estimate: 31%) mainly due to a favourable product mix. EBITDA grew 16% to \| 122 crore (I-direct estimate: \| 154 crore) Adjusted net profit increased 28% YoY to \| 85 crore (I-direct... pdf Copy Link Share on Share on Share on Share on Alert
	06 Nov 2017	Natco Pharma	Edelweiss Reco Target	858.80	991.00	961.45 (-10.68%)	Target met	Hold	pdf post cache		Broker Report Natco Pharmaceuticals Limited - Result Update Q2FY18 Edelweiss Natco Pharmaceuticals Limited (NATCO) Q2FY18: Underperformance led by pricing pressure across; exciting launches ahead. pdf Copy Link Share on Share on Share on Share on Alert
	16 Oct 2017	Natco Pharma	Axis Direct	858.80	1240.00	989.00 (-13.16%)		Buy	pdf post cache		Broker Report Company Update:Natco Pharma Axis Direct Natco's (partner Mylan) 1st generic approval for gCopaxone 40mg (USD 2.9 bn market; possibility of 180 day exclusivity) and 2nd generic approval for gCopaxone 20mg (USD 700 mn market) demonstrate its R&D; ability to execute on complex generics with intricate chemistry and complex processes pdf Copy Link Share on Share on Share on Share on Alert
	12 Oct 2017	Natco Pharma	Axis Direct Target	858.80	1240.00	989.70 (-13.23%)		Buy	pdf post cache		Broker Report Company Update:Natco Pharma Axis Direct Natcos (partner Mylan) 1st generic approval for gCopaxone 40mg (USD 2.9 bn market; possibility of 180 day exclusivity) and 2nd generic approval for gCopaxone 20mg (USD 700 mn market) demonstrate its R&D; ability to execute on complex generics with intricate chemistry and complex processes pdf Copy Link Share on Share on Share on Share on Alert
	09 Aug 2017	Natco Pharma	Edelweiss	858.80	1213.00	830.60 (3.40%)		Buy	pdf post cache		Broker Report Natco Pharmaceuticals Ltd - Result Update Q1FY18 Edelweiss Natco Pharmaceuticals Ltd (NPL) reported a topline of INR 428 crs, which is 5% higher than our estimates. The strong uptick in numbers has been primarily on account of incremental profit... pdf Copy Link Share on Share on Share on Share on Alert
	09 Aug 2017	Natco Pharma	ICICI Securities Limited Reco Target	858.80	955.00	830.60 (3.40%)	Target met	Hold	pdf post cache		Broker Report Natco Pharma Limited ICICI Securities Limited EBITDA margins improved 801 bps YoY to 30.7% (I-direct estimate: 27.5%) mainly due to a favourable product mix. EBITDA grew 77% to \| 137 crore (I-direct estimate: \| 109 crore) Adjusted net profit increased 96% YoY to \| 93 crore (I-direct... pdf Copy Link Share on Share on Share on Share on Alert
	08 Aug 2017	Natco Pharma	HDFC Securities	858.80		925.25 (-7.18%)		Results Update	pdf post cache		Broker Report Natco Pharma Ltd Q1FY18 results comment HDFC Securities Revenue decreased by 25.91% to Rs. 428.1 Cr in Q1FY18 when compared to the previous quarter. Revenue decreased by 25.91% to Rs. 428.1 Cr in Q1FY18 when compared to the previous quarter. pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners